Our final panel, “Making the Right Edit: New Waves Being Made in the Field of Genetic Medicines” featured Devyn Smith, CEO of Arbor Biotechnologies, Daniel Dornbusch, CEO of Excision BioTherapeutics, and Alethia Young, CFO of Graphite Bio. The panel was moderated by Olivia Brayer and Jennifer Kim.

• Arbor Biotechnologies discussed the importance of having the right strategies and executing on them.

• Excision is developing CRISPR-based therapies as potential cures for viral infectious diseases and has become the first and only company in history to cure HIV with a therapeutic in an animal model. Data from its Phase 1/2 trial in HIV could come in 2023.

• Graphite Bio, a next-generation gene editing company, had its first patient clinic in August and expects to have proof of concept data by mid-2023.

#Cantor #CantorFitzgerald #CantorHealthcare #CantorConferenceSeries